(Q52891891)

9 May 2018

title

Rapamycin inhibits osteoclast formation in giant cell tumor of bone through the C/EBPβ - MafB axis. (English)

1 reference

9 May 2018

1 reference

1 reference

3

1 reference

9 May 2018

author name string

Jeske J Smink

series ordinal

1

1 reference

9 May 2018

Per-Ulf Tunn

series ordinal

2

1 reference

9 May 2018

publication date

10 November 2011

1 reference

9 May 2018

Journal of Molecular Medicine

published in

1 reference

9 May 2018

volume

90

1 reference

9 May 2018

issue

1

1 reference

9 May 2018

page(s)

25-30

1 reference

9 May 2018

Giant cell tumour of bone.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

The osteoclast: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

Transcription factor C/EBPbeta isoform ratio regulates osteoclastogenesis through MafB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

Rapamycin and the transcription factor C/EBPbeta as a switch in osteoclast differentiation: implications for lytic bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

C/EBPbetaDeltauORF mice--a genetic model for uORF-mediated translational control in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

Upstream open reading frames: molecular switches in (patho)physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

Giant cell tumour of bone: morphological, biological and histogenetical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

Future anti-catabolic therapeutic targets in bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

New drugs in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-011-0823-6

MafB negatively regulates RANKL-mediated osteoclast differentiation

21 January 2018

1 reference

12 December 2020

Expression of osteoclast differentiation signals by stromal elements of giant cell tumors

1 reference

12 December 2020

Translational control of C/EBPalpha and C/EBPbeta isoform expression.

1 reference

12 December 2020

CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression.

1 reference

12 December 2020

Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone

1 reference

12 December 2020

Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis.

1 reference

12 December 2020

RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone

1 reference

12 December 2020

10.1007/S00109-011-0823-6

Identifiers

DOI

1 reference

9 May 2018

release_4klccizdrbbmpl4acbnpxvl6ju

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4klccizdrbbmpl4acbnpxvl6ju

24 November 2022

mapped directly with Wikidata item

1 reference

9 May 2018